(Epoetin alfa)


Drug updated on 10/23/2023

Dosage FormInjection (intravenous/subcutaneous: 2,000 Units/mL, 3,000 Units/mL, 4,000 Units/mL, and 10,000)
Drug ClassErythropoiesis-stimulating agent
Ongoing and Completed StudiesClinicalTrials.gov


  • For treatment of anemia due to chronic kidney disease (CKD) in patients on dialysis and not on dialysis.
  • For treatment of anemia due to Zidovudine in patients with HIV-infection.
  • For treatment of anemia due to the effects of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy.
  • For reduction of allogeneic RBC transfusions in patients undergoing elective, noncardiac, nonvascular surgery.

Product Monograph / Prescribing Information

Document TitleYearSource
Epogen (epoetin alfa) Prescribing Information.2018Amgen Inc., Thousand Oaks, CA

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines